Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies (NYSE: A) has been recognized as one of the top 100 Most JUST companies, ranking 35 in the annual list by Just Capital and CNBC. This marks its fifth consecutive year in the ranking, with Agilent leading its sector in employee treatment, customer satisfaction, and environmental impact. Agilent's commitment to corporate responsibility is underlined by its recognition as a Great Place to Work in 20 countries and being listed among the best workplaces in health care by Fortune. The company's revenue reached $6.85 billion in fiscal 2022, employing 18,000 people globally.
Agilent Technologies Inc. (NYSE: A) has announced a new share repurchase program, authorizing up to $2 billion to buy back its common stock starting March 1. This initiative replaces the existing program aimed at minimizing share dilution. CFO Bob McMahon emphasized that this program is crucial for balanced capital deployment, focusing on growth and delivering strong returns to shareholders. Repurchases will depend on various factors including stock price and market conditions.
Agilent Technologies (NYSE: A) is investing approximately $725 million to double its manufacturing capacity for therapeutic nucleic acids, addressing strong demand in a growing $1 billion market. This investment will facilitate the production of short DNA and RNA molecules used in therapies for various diseases, including cancer. Agilent anticipates shipments from the new facility in location value="LU/us.co.freick"Frederick, Colorado to commence in 2026, with estimates projecting the market will reach $2.4 billion by 2027.
Agilent Technologies (NYSE: A) has partnered with Akoya Biosciences (NASDAQ: AKYA) to commercialize end-to-end workflow solutions for tissue biomarker analysis in companion diagnostic development. This collaboration aims to create multiplex-immunohistochemistry diagnostic solutions, integrating Agilent's Dako Omnis autostaining instrument and Akoya's PhenoImager HT imaging platform. The partnership enhances clinical research capabilities for biopharma companies developing cancer therapeutics, enabling improved patient stratification and biomarker validation.
Agilent Technologies (NYSE: A) has acquired Avida Biomed, a life sciences firm specializing in target enrichment workflows for cancer research. This acquisition enhances Agilent's SureSelect portfolio and positions the company for expansion in clinical research and diagnostics. Avida's innovative technology allows for simultaneous genomic and DNA methylation profiling from a single sample, improving efficiency. This strategic move will enable Agilent to better support oncology researchers and advance precision medicine applications globally.
Agilent Technologies (NYSE: A) announced that CEO Mike McMullen and CFO Bob McMahon will present at the Goldman Sachs Healthcare CEOs Unscripted Conference on January 5, 2023, at 2:05 p.m. ET, and the J.P. Morgan Healthcare Conference on January 10, 2023, at 9:00 a.m. PT. Both events will be webcasted live, accessible via Agilent's Investor Relations website. Agilent is recognized as a leader in the life sciences and diagnostics fields, generating $6.85 billion in revenue in fiscal 2022 and employing 18,000 people globally.
Agilent Technologies (NYSE: A) has received FDA approval for the Resolution ctDx FIRST, a liquid biopsy companion diagnostic to identify advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benefit from KRAZATI (adagrasib). This marks the first FDA-approved liquid biopsy NGS assay as a CDx for KRAZATI. The assay provides broad genomic profiling on 109 genes, facilitating treatment decisions for approximately 14% of NSCLC patients with KRAS mutations and 32% with EGFR mutations. The minimally invasive approach allows for faster diagnostics, benefiting patient care.
Summary not available.
Agilent Technologies Inc. has opened a new Customer Experience Center (CEC) in Lexington, Massachusetts, aimed at enhancing customer education in genomics and diagnostics. This facility will act as a hub for hands-on training, product demonstrations, and workflow solutions, catering to a growing base of pathologists, clinicians, and researchers. The CEC's strategic location ensures accessibility for a high concentration of Agilent's customers. The company generated $6.85 billion in revenue in fiscal 2022, underlining its significant market presence.
Agilent Technologies (NYSE: A) has become the first 'Angel' level sponsor of My Green Lab, enhancing its support for laboratory sustainability. This partnership allows Agilent to access strategic insights to aid customers in achieving sustainability goals. The company also sponsors the Green Lab Certification program, which promotes best practices in lab sustainability. Agilent's labs in Germany, the UK, and Santa Clara have achieved the highest certification level. This initiative aligns with Agilent's commitment to environmental and social governance (ESG) standards.